Amino acid PET imaging could represent a biomarker for the evaluation of IDH inhibitor treatments for patients with refractory IDH-mutated gliomas
Amino acid PET imaging could represent a biomarker for the evaluation of IDH inhibitor treatments for patients with refractory IDH-mutated gliomas In fact, this study will allow us to assess, using Rano 1.0 criteria for PET and Rano 2.0 criteria for MRI, which of the two examinations is most effective in assessing the efficacy of anti-IDH treatment patients with refractory IDH-mutated gliomas.
Study Type
OBSERVATIONAL
Enrollment
22
Patients received 18-fluoroDopa then a PET exam
CHRU of NANCY
Vandœuvre-lès-Nancy, France
Compare the performance between amino acid PET and brain MRI to assess a treatment efficacy
Comparison between early therapeutic response according to RANO 1.0 and RANO 2.0 PET criteria and tumor progression at 6 months
Time frame: one day
Compare the performance between amino acid PET and brain MRI to assess a treatment efficacy for the identification of lesions
Determination of the number of lesions assessable by amino acid PET according to RANO 1.0 PET criteria and by MRI according to RANO 2.0 criteria
Time frame: one day
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.